Table S2.
Treatment patterns for patients with advanced NSCLC, nonsquamous histology and EGFR/ALK-negative or unknown status, or not testeda
| Treatment regimen | EGFR/ALK negative/unknown |
|---|---|
| First-line therapy | (N=83) |
| Platinum combination | 74 (89) |
| Carboplatin, paclitaxel | 22 (27) |
| Cisplatin, pemetrexed | 10 (12) |
| Carboplatin, pemetrexed | 8 (10) |
| Bevacizumab, carboplatin, paclitaxel | 7 (8) |
| Cisplatin, gemcitabine | 4 (5) |
| Single agent | 9 (11) |
| Docetaxel | 3 (4) |
| Paclitaxel | 2 (2) |
| Tegafur/gimeracil/oteracilb | 2 (2) |
| Carboplatin | 1 (1) |
| Pemetrexed | 1 (1) |
| Second-line therapy | n=43 |
| Platinum combination | 9 (21) |
| Carboplatin, paclitaxel | 2 (5) |
| Cisplatin, pemetrexed | 2 (5) |
| Bevacizumab, carboplatin, erlotinib, paclitaxel | 1 (2) |
| Bevacizumab, carboplatin, paclitaxel | 1 (2) |
| Bevacizumab, carboplatin, pemetrexed | 1 (2) |
| Nonplatinum combination | 2 (5) |
| Bevacizumab, pemetrexed | 1 (2) |
| Gemcitabine, vinorelbine | 1 (2) |
| Single agent | 29 (67) |
| Docetaxel | 15 (35) |
| Pemetrexed | 14 (33) |
| EGFR/ALK TKI | 3 (7) |
| Erlotinib | 3 (7) |
| Third-line therapy | n=22 |
| Platinum combination | 7 (32) |
| Carboplatin, paclitaxel | 3 (14) |
| Carboplatin, tegafur/gimeracil/oteracil | 2 (9) |
| Albumin-bound paclitaxel, carboplatin | 1 (5) |
| Albumin-bound paclitaxel, bevacizumab, carboplatin | 1 (5) |
| Nonplatinum combination | 1 (5) |
| Albumin-bound paclitaxel, erlotinib, gemcitabine, vinorelbine | 1 (5) |
| Single agent | 11 (50) |
| Docetaxel | 5 (23) |
| Pemetrexed | 4 (18) |
| Amrubicin HCl | 1 (5) |
| Gemcitabine | 1 (5) |
| EGFR/ALK TKI | 3 (14) |
| Erlotinib | 3 (14) |
Notes: Data are n (%). Percentages may not be additive because of rounding.
a
The top 5 regimens for each category are presented.
b
Oral anticancer drug composed of tegafur, gimeracil, and oteracil potassium at a molar ratio of 1:1:0.4.
Abbreviations: ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor.